- LOTTE BIOLOGICS has held a topping-out ceremony for Plant 1 at its Songdo Bio Campus in Incheon, marking the completion of structural construction in 18 months.
- The facility, due for completion in 2026, will add 120,000 litres of capacity and begin commercial manufacturing in 2027.
LOTTE BIOLOGICS announced that it has completed the structural framework of Plant 1 at its Songdo Bio Campus in Incheon. The milestone was celebrated on 10 September with a topping-out ceremony attended by executives from across the LOTTE Group.
The event follows the company’s October 2023 land purchase agreement with the Incheon Free Economic Zone Authority and the start of construction in March 2024. Plant 1 will serve as an antibody therapeutic manufacturing facility with a capacity of 120,000 litres. It is expected to be completed in 2026 and begin contract manufacturing operations in the first half of 2027.
Upon completion, the Songdo site will form part of LOTTE BIOLOGICS’ plan to build three facilities, each with the same capacity. Combined with the 40,000-litre output of its Syracuse Bio Campus in the United States, the company’s global production volume will reach 160,000 litres. The Songdo facility is designed as a Smart Factory with advanced technology and flexible processes to meet diverse customer needs.
CEO James Park described the event as a pivotal step for both the company and the wider sector. “The topping-out ceremony for Plant 1 is not just a crucial stepping stone for LOTTE BIOLOGICS’ growth; it is a meaningful moment that opens a new chapter for Korea’s bio-industry,” he said.
Now in its fourth year, LOTTE BIOLOGICS continues to strengthen its position as a global CDMO. Recent contracts include deals with a U.S. biotech firm, British company OTTIMO Pharma, and an Asia-based partner for Antibody-Drug Conjugates. Earlier this year, the company also completed a $100 million ADC facility at its Syracuse site.
